COMPASS PATHWAYS PLC - AMERICAN DEPOSITORY SHARES

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

19 Dec 2023 16:05:00 By Nasdaq GlobeNewswire

Compass Pathways appoints Teri Loxam as Chief Financial Officer

07 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

06 Dec 2023 16:00:09 By Nasdaq GlobeNewswire

Compass Pathways to participate in upcoming Evercore investor conference

24 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

15 Nov 2023 04:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways announces CFO transition

26 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023

24 Oct 2023 16:01:00 By Nasdaq GlobeNewswire

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

18 Sep 2023 16:31:00 By Nasdaq GlobeNewswire

COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

06 Sep 2023 04:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming September investor conferences

29 Aug 2023 16:30:50 By Nasdaq GlobeNewswire

COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

16 Aug 2023 08:58:20 By Nasdaq GlobeNewswire

COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights  

03 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023

31 Jul 2023 08:32:44 By Nasdaq GlobeNewswire

COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology

17 Jul 2023 04:00:00 By Nasdaq GlobeNewswire

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin

13 Jul 2023 04:00:00 By Nasdaq GlobeNewswire

American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies

06 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital

05 Jul 2023 07:00:35 By Nasdaq GlobeNewswire

COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferences

16 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

COMPASS Pathways' key patents upheld by the US Patent and Trademark Office

06 Jun 2023 08:00:00 By Nasdaq GlobeNewswire